摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-Benzyloxy-thiobenzamid | 24723-35-1

中文名称
——
中文别名
——
英文名称
3-Benzyloxy-thiobenzamid
英文别名
3-Phenylmethoxybenzenecarbothioamide
3-Benzyloxy-thiobenzamid化学式
CAS
24723-35-1
化学式
C14H13NOS
mdl
——
分子量
243.329
InChiKey
ODFBZXPEUCMTEH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.07
  • 拓扑面积:
    67.3
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-Benzyloxy-thiobenzamid吡啶 、 lithium aluminium tetrahydride 作用下, 以 乙醚乙醇 为溶剂, 生成 [4-Methyl-2-(3-phenylmethoxyphenyl)-1,3-thiazol-5-yl]methanol
    参考文献:
    名称:
    Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents
    摘要:
    Therapeutics of metastatic or triple-negative breast cancer are still challenging in clinical. Herein we demonstrated the design and optimization of a series of hybrid of 2,4-diaminopyrimidine and arylthiazole derivatives for their anti-proliferative properties against two breast cancer cell lines (MCF-7 as human breast cancer and MDA-MB-231 as triple-negative breast cancer). More importantly, some of those compounds with potent antiproliferative activities also indicated excellent inhibitory activities against MDA-MB-231 cell migration. These results suggested that the new series of hybridation of arylthiazoles and aminopyrimidines could be identified and developed as novel highly potential anticancer agents against the triple-negative breast cancer as well as metastatic one in the future. (C) 2015 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2015.04.027
  • 作为产物:
    描述:
    3-(苄氧基)苯甲腈 在 calcium hydride 、 硫代乙酸 作用下, 以 neat (no solvent) 为溶剂, 反应 3.25h, 生成 3-Benzyloxy-thiobenzamid
    参考文献:
    名称:
    Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents
    摘要:
    Therapeutics of metastatic or triple-negative breast cancer are still challenging in clinical. Herein we demonstrated the design and optimization of a series of hybrid of 2,4-diaminopyrimidine and arylthiazole derivatives for their anti-proliferative properties against two breast cancer cell lines (MCF-7 as human breast cancer and MDA-MB-231 as triple-negative breast cancer). More importantly, some of those compounds with potent antiproliferative activities also indicated excellent inhibitory activities against MDA-MB-231 cell migration. These results suggested that the new series of hybridation of arylthiazoles and aminopyrimidines could be identified and developed as novel highly potential anticancer agents against the triple-negative breast cancer as well as metastatic one in the future. (C) 2015 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2015.04.027
点击查看最新优质反应信息

文献信息

  • PROCESS FOR PRODUCING TETRAZOLE COMPOUND AND INTERMEDIATE THEREFOR
    申请人:SUMITOMO CHEMICAL COMPANY LIMITED
    公开号:EP0711762A1
    公开(公告)日:1996-05-15
    There are disclosed an industrially favorable process for producing a tetrazole compound of general formula (1): characterized in that a nitrile of general formula (2):         R¹CN     (2) is reacted with hydrazine or a salt thereof in the presence of a catalyst, followed by reaction with a nitrous acid compound of general formula (3):         ANO₂     (3) or a nitrile of general formula (2) is reacted with hydrogen sulfide, followed by reaction with an alkyl halide of general formula (4):         R⁴J     (4) with hydrazine or a salt thereof, and then with a nitrous acid compound of general formula (3); and an intermediate of general formula (5):         R¹C(=R⁵)R⁶     (5) which is useful for the production of the tetrazole compound (in which R¹ to R⁶, A and J in the above formulas are as defined in the specification).
    本发明公开了一种生产通式(1)四唑化合物的工业化生产工艺: 其特征在于,通式(2)的腈: R¹CN (2) 在催化剂存在下与肼或其盐反应,然后与通式(3)的亚硝酸化合物反应: ANO₂ (3) 或通式(2)的腈与硫化氢反应,然后与通式(4)的烷基卤化物反应: R⁴J (4) 与肼或其盐反应,然后与通式(3)的亚硝酸化合物反应;以及通式(5)的中间体: R¹C(=R⁵)R⁶ (5) 其中上述式中的 R¹ 至 R⁶、A 和 J 如说明书中所定义)。
  • OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF
    申请人:TREGA BIOSCIENCES, INC.
    公开号:EP1126833A2
    公开(公告)日:2001-08-29
  • EP1126833A4
    申请人:——
    公开号:EP1126833A4
    公开(公告)日:2004-09-08
  • US5874593A
    申请人:——
    公开号:US5874593A
    公开(公告)日:1999-02-23
  • US6191289B1
    申请人:——
    公开号:US6191289B1
    公开(公告)日:2001-02-20
查看更多